LAB in the 13F filings
Standard Biotools Inc · CUSIP 34385P108
- Quarter end
- 30 Jun 2026
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 13 Aug 2026
- Managers listing it
- 21
- at least, of 95 tracked, among listed positions
- Comparable managers
- 91
- filed both Q1 2026 and Q2 2026; 1 listed it in both
- Shares listed
- 82,077,181
- combined, among listed positions
- Reported value
- $67m
- combined, at the quarter end
Among the 91 comparable managers: 18 buyers (opened or added shares) and 5 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +13,186,236.
Managers listing LAB in Q2 2026
21 of 21 holders
Largest increases and reductions, by shares
Increases
- D. E. Shaw & Co.existing position · 2,818,026 shares now+2,618,942
- Jane Street Group LLCnew position · 2,514,299 shares now+2,514,299
- Arrowstreet Capital LPnew position · 1,991,426 shares now+1,991,426
- Millennium Management LLCexisting position · 3,512,665 shares now+1,410,650
- Citadel Advisors LLCexisting position · 2,348,570 shares now+1,123,260
Reductions
- Invesco Ltdexisting position · 221,906 shares now-36,438
- Fidelity (FMR LLC)existing position · 3,153 shares now-13,356
New positions and exits
New (11)
- Jane Street Group LLC$2.1m
- Arrowstreet Capital LP$1.6m
- Renaissance Technologies LLC$816k
- Man Group PLC$611k
- Squarepoint Ops LLC$228k
- Brevan Howard Capital Management LP$199k
- Schonfeld Strategic Advisors LLC$98k
- Hudson Bay Capital Management LP$53k
- Acadian Asset Management LLC$43k
- Balyasny Asset Management LLC$32k
Exited (3)
- AllianceBernstein LPwas $404k
- T. Rowe Price Associates Incwas $187k
- Janus Henderson Group Ltdwas $121k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q3 2015 | 1 | $6.5m | n.a. | n.a. |
| Q4 2015 | 1 | $8.6m | n.a. | n.a. |
| Q1 2016 | 2 | $9.9m | n.a. | n.a. |
| Q2 2016 | 3 | $10m | n.a. | n.a. |
| Q3 2016 | 2 | $6.7m | n.a. | n.a. |
| Q4 2016 | 2 | $6.1m | n.a. | n.a. |
| Q1 2017 | 1 | $100k | n.a. | n.a. |
| Q1 2018 | 1 | $873k | n.a. | n.a. |
| Q2 2018 | 2 | $2.0m | n.a. | n.a. |
| Q3 2018 | 4 | $41m | n.a. | n.a. |
| Q4 2018 | 4 | $60m | n.a. | n.a. |
| Q1 2019 | 6 | $101m | n.a. | n.a. |
| Q2 2019 | 5 | $89m | n.a. | n.a. |
| Q3 2019 | 3 | $9.5m | n.a. | n.a. |
| Q4 2019 | 1 | $5.9m | n.a. | n.a. |
| Q1 2020 | 2 | $4.3m | n.a. | n.a. |
| Q2 2020 | 1 | $5.3m | n.a. | n.a. |
| Q3 2020 | 5 | $51m | n.a. | n.a. |
| Q4 2020 | 4 | $13m | n.a. | n.a. |
| Q1 2021 | 1 | $2.2m | n.a. | n.a. |
| Q2 2021 | 1 | $1.2m | n.a. | n.a. |
| Q3 2021 | 1 | $843k | n.a. | n.a. |
| Q4 2021 | 1 | $585k | n.a. | n.a. |
| Q1 2024 | 2 | $194m | 2 | 0 |
| Q2 2024 | 2 | $126m | 0 | 1 |
| Q3 2024 | 2 | $130m | 0 | 1 |
| Q4 2024 | 2 | $108m | 0 | 1 |
| Q1 2025 | 2 | $67m | 1 | 0 |
| Q2 2025 | 2 | $74m | 0 | 1 |
| Q3 2025 | 2 | $80m | 0 | 1 |
| Q4 2025 | 2 | $79m | 7 | 5 |
| Q1 2026 | 1 | $54m | 8 | 4 |
| Q2 2026 | 1 | $48m | 18 | 5 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
LAB and LLY →LAB and JNJ →LAB and VRTX →Choose a stock to compare with LAB →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own LAB, latest filings →Back to the 13F Explorer →